Cambodia vs Papua New Guinea: Prevalence rate of hypertension in men aged 30-79
Cambodia
25.8
in 2019
Papua New Guinea
25.4
in 2019
Cambodia rank
187th
Papua New Guinea rank
189th
Prevalence rate of hypertension in men aged 30-79 over time
- Cambodia
- Papua New Guinea
How they compare
Cambodia currently reports 25.8 against 25.4 in Papua New Guinea, a difference of 0.4.
Across all 30 years both countries report, Cambodia has been ahead every year.
Cambodia ranks 187th and Papua New Guinea ranks 189th of 195 countries.
Cambodia has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Cambodia | Papua New Guinea | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 24.02 | 21.95 | 2.07 | Cambodia |
| 2000s | 24.81 | 21.36 | 3.45 | Cambodia |
| 2010s | 25.34 | 23.89 | 1.45 | Cambodia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of hypertension in men aged 30-79, Cambodia or Papua New Guinea?
- Cambodia, at 25.8 against 25.4 in Papua New Guinea as of 2019.
- What is the difference in prevalence rate of hypertension in men aged 30-79 between Cambodia and Papua New Guinea?
- 0.4, with Cambodia ahead.
- How many years of comparable data are there for Cambodia and Papua New Guinea?
- 30 years are reported by both, from 1990 to 2019.
- How do Cambodia and Papua New Guinea rank globally for prevalence rate of hypertension in men aged 30-79?
- Cambodia ranks 187th and Papua New Guinea ranks 189th of 195 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of hypertension in men aged 30-79. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of male population with hypertension, based on population representative surveys and statistical modeling. Hypertension is a risk factor for chronic complications, including cardiovascular disease, and premature death.